News
4 October, 2022 - 04:00 (CEST)
Announcement
M
The EOI for artesunate/pyronaridine products is being revised to bring it in line with currently available artesunate/pyronaridine comparator products. In particular, the revision to invited paediatric products introduces artesunate/pyronaridine granules for oral suspension 20mg/60mg, replacing artesunate/pyronaridine tablets 20mg/60mg. This revision clarifies the appropriate comparator product for each invited product and minimizes the risk of confusion in clinical practice.